Screening patients with prolonged neuromuscular blockade after succinylcholine and mivacurium

Anesthesia and Analgesia

Volumn 94, Issue 2, 2002, Pages 461-466

  Cerf, Charles ^a   Mesguish, Martine ^a   Gabriel, Inanna ^a   Amselem, Serge ^a   Duvaldestin, Philippe ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE; MIVACURIUM; SUXAMETHONIUM;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE MUTATION; GENETIC SCREENING; GENETIC VARIABILITY; HETEROZYGOSITY; HUMAN; INFANT; MALE; MOLECULAR BIOLOGY; NEUROMUSCULAR BLOCKING; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCREENING TEST;

EID: 0036150466     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/00000539-200202000-00044     Document Type: Article

References (37)

1. Plasma cholinesterase: Gene and variations
2. Identification of human plasma cholinesterase variants in 6688 individuals using biochemical analysis
3. Prolonged neuromuscular blockade following suxamethonium in a patient with a normal genotype
4. Markedly prolonged paralysis after mivacurium in a patient apparently heterozygous for the atypical and usual pseudocholinesterase alleles by conventional biochemical testing
5. Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase
6. Butyrylcholinesterase variants and the new methods of molecular biology
7. Diagnosis of genetic disorders at the DNA level
8. Dibucaine number measured with the Ektachem
9. Causes and prevention of prolonged apnea with succinylcholine
10. Familial incidence of low pseudocholinesterase level
11. DNA mutation associated with the human butyrylcholinesterase J-variant
12. DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites
13. Identification of human plasma cholinesterase variants using molecular biological techniques
14. Dose-dependent effect of metoclopramide on cholinesterases and suxamethonium metabolism
15. Qualitative and quantitative defects of pseudocholinesterase activity
16. Plasma cholinesterase and abnormal reaction to succinylcholine: Twenty years' experience with the Danish Cholinesterase Research Unit
17. Contribution of hereditary factors to the response to drugs
18. Human cholinesterase (pseudocholinesterase): Genetic variants and their recognition
19. A study of pseudocholinesterase in 78 cases of apnoea following suxamethonium
20. Prolonged apnoea after suxamethonium: An analysis of the first 225 cases reported to the Danish Cholinesterase Research Unit
21. Initial experiences with the cholinesterase research unit
22. Mivacurium-induced neuromuscular blockade in patients with atypical plasma cholinesterase
23. Correlation of succinylcholine duration of action with plasma cholinesterase activity in subjects with the genotypically normal enzyme
24. Influence of plasma cholinesterase activity on recovery from mivacurium-induced neuromuscular blockade in phenotypically normal patients
25. Does age or pseudocholinesterase activity predict mivacurium infusion rate in children?
26. A method for the detection of atypical forms for human cholinesterase: Determination of dibucaine number
27. Plasma cholinesterase phenotyping with use of visible-region spectrophotometry
28. Aetiology of prolonged apnoea after suxamethonium
29. Intérêt du monitorage de la curarisation lors d'un bloc neuromusculaire prolongé par mivacurium
30. Bloc neuromusculaire prolongé au mivacurium chez cinq patients homozygotes pour le phénotype atypique de la butyrylcholinestérase
31. Prolonged neuromuscular block from mivacurium in two patients with cholinesterase deficiency
32. Prolonged neuromuscular block after mivacurium from plasma pseudocholinesterases deficiency
33. Prolonged neuromuscular block following mivacurium
34. Curarisation prolongé par mivacurium
35. Prolonged neuromuscular block after mivacurium
36. Bloc neuromusculaire prolongé après injection de mivacurium
37. Curarisation prolongé chez une patiente traitée par cyclophosphamide